BioSpace News Archive

ORIC Pharmaceuticals, Inc. today announced multiple presentations, including initial clinical data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, will be presenting design and rationale details of a Phase 1 trial evaluating KIN-2787 during the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the Untied States Patent and Trademark Office (USPTO) for a patent entitled “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase.”

Skye Bioscience, Inc., a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development.

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly endometriosis.

Tekni-Plex Healthcare has acquired precision extrusion manufacturer Johnson Plastic Group (JPG) as part of a strategy to expand the company’s patient care solutions platform.

iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens (“iSpecimen” or the “Company”), today announced it is expanding its human biospecimen supplier network to offer increasingly comprehensive selections of whole blood, plasma and other biofluids to help accelerate the development of liquid biopsies.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial markets.

Venclose Inc. today announced FDA 510(k) clearance for Venclose Maven

Lassen Therapeutics today announced the appointment of a highly experienced industry executive and recognized clinical thought leaders to its team. Lisa Olson, Ph.D., joins the Board of Directors and Bill Bradford, M.D., Ph.D., Paul W. Noble, M.D., and Toby Maher, M.B.B.S., M.Sc., Ph.D.